Retinoaspis is a specialized nutraceutical for the prevention and treatment of diabetic retinopathy and retinal vein occlusion.
Retinoaspis manages diabetic retinopathy by supporting the metabolism, structure and function of retinal cells. Retinoaspis has a strong anti-inflammatory effect by promoting the production of anti-inflammatory cytokines. A key anti-inflammatory component is docosahexaenoic acid (DHA), which is a necessary component for the normal function of the organism and cannot be synthesized by itself. Retinoaspis also has an antioxidant effect, providing the necessary antioxidant mechanism in the retina. Astaxanthin, which is contained in the product, is literally hundreds of times stronger than other antioxidant molecules. Astaxanthin comes from the algae of the genus Haematococcus pluvialis and is a natural carotenoid. Retinoaspis covers the body’s vitamin needs, regulates homocysteine levels and provides an additional anti-inflammatory effect with vitamin B12.
Commercial rights & brand holder: Aniva International S.A.
The product should not be used as a substitute of a well-balanced diet. This product is not intended to prevent, treat or cure any human disease.
